Recent research published in Blood highlights a promising discovery in the fight against leukemia. Scientists have identified that itraconazole in AML treatment could serve as a powerful tool by targeting the metabolic vulnerabilities of cancer cells. Specifically, this FDA-approved antifungal drug acts as a potent inhibitor of oxidative phosphorylation (OXPHOS), a process that leukemic stem cells (LSCs) depend on for survival and resistance.

Mechanism of Action: Itraconazole in AML Treatment

The study utilized a high-throughput drug-repurposing screen to find clinically safe OXPHOS inhibitors. It revealed that itraconazole interferes with the tricarboxylic acid (TCA) cycle. Mechanistically, the drug targets CYP51A1, a member of the cytochrome P450 family. While traditionally known for its antifungal properties, CYP51A1 also plays a critical role in mitochondrial respiration and electron transport chain (ETC) complex I activity within AML cells. By inhibiting this pathway, itraconazole effectively starves the leukemia cells of their energy source.

Furthermore, researchers demonstrated that over-expressing yeast NADH dehydrogenase-1 (NDI1) could restore mitochondrial function. This finding confirms that the drug's primary impact is on the NADH oxidation process. Consequently, the researchers proved that the inhibition is specific to the metabolic machinery of the leukemia cells. Therefore, this mechanism provides a clear pathway for clinical application.

Eradicating Leukemic Stem Cells

One of the most significant challenges in treating acute myeloid leukemia is the persistence of therapy-resistant leukemic stem cells. These cells often survive standard chemotherapy, leading to relapse. However, this research shows that combining itraconazole with cytarabine can effectively target and eradicate these LSCs. Moreover, using patient-derived cells and xenograft models, the study illustrated that this combination therapy significantly reduces the leukemic burden.

Because itraconazole is already FDA-approved and widely used for fungal infections, its safety profile is well-documented. Consequently, this makes it an ideal candidate for rapid clinical translation. Doctors may soon have a cost-effective and accessible option to enhance standard induction therapy in India and worldwide.

Frequently Asked Questions

How does itraconazole help in AML treatment?

Itraconazole inhibits oxidative phosphorylation (OXPHOS) by targeting ETC complex I activity. This disrupts the energy supply of leukemic stem cells, making them more susceptible to chemotherapy like cytarabine.

What is the role of CYP51A1 in leukemia cells?

In AML cells, CYP51A1 is involved in maintaining mitochondrial respiration. The antifungal drug itraconazole inhibits this protein, thereby blocking the electron transport chain and halting the TCA cycle.

Is this treatment currently available for AML patients?

While itraconazole is an FDA-approved drug for fungal infections, its use in AML is currently a subject of advanced pre-clinical research. Patients should consult their oncologists regarding clinical trials or emerging treatment protocols.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a recommendation for any specific treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Himonas E et al. A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia. Blood. 2026 Feb 24. doi: undefined. PMID: 41734389.


2. Lagadinou ED et al. AML cells are dependent on mitochondrial oxidative phosphorylation. Frontiers in Oncology. 2022.


3. ClinicalTrials.gov. Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia. NCT07069933.